SGLT-2 Therapy Center

CV data added to labels for treatments containing empagliflozin.

In this week's Homerun Slides, the vital stats of patients on the placebo and empagliflozin 10- and 25-gram study.

What do we need to tell our patients about preventing the risk for death?

Dr. Jeffrey Mechanick talks with Diabetes in Control Publisher Steve Freed at the 2016 AACE Meeting. In part 9 of this Exclusive Interview, Dr. Mechanick reiterates his call for the individualization of diabetes care.

In this week's Homerun Slides, the baseline characteristics of the randomized, placebo-controlled cardiovascular outcome trial of empagliflozin.

2016 in SGLT-2 Inhibitors: saw a host of important information on SGLT-2 inhibitors. Catch up with our best of 2016 articles.

In this week's Homerun Slides, EMPA-REG Outcome, examining the long-term effects of empagliflozin versus using a placebo on the heart and mortality risk in patients with type 2.

The US Food and Drug Administration (FDA) has approved empagliflozin (Jardiance, Boehringer Ingelheim Pharmaceuticals Inc and Eli Lilly) for the new indication of improving survival in adults with type 2 diabetes and cardiovascular disease (CVD).

2016 could be remembered for the year when the diabetes class of drugs known as the SGLT-2 inhibitors has made a huge impact on the lives of those with type 2 diabetes today and into the future. Never in the history of the treatment for diabetes have we seen a new drug entry that reduce the risk for dying for those with diabetes.

In this week's Homerun Slides: EMPA-REG Outcome Trial Part 1: Meta-analysis of intensive glucose control in T2DM.